转移性尿路上皮癌一线治疗的进展。
Advancements in the front-line treatment of metastatic urothelial carcinoma.
发表日期：2024 Aug 29
作者：
Sarah M H Einerhand, Michiel S van der Heijden
来源：
European Urology Focus
摘要：
CheckMate-901（吉西他滨-顺铂加纳武单抗）试验和 EV-302（enfortumab-vedotin 加派姆单抗；EV P）试验均显示，与基于标准（顺）铂的化疗相比，OS 显着改善。效果大小以及 EV P 更广泛的资格标准使该方案成为一线 mUC 治疗新护理标准的首选候选方案。版权所有 © 2024。由 Elsevier B.V. 出版。
Both the CheckMate-901 (gemcitabine-cisplatin plus nivolumab) trial and the EV-302 (enfortumab-vedotin plus pembrolizumab; EV+P) trial have shown a significant improvement in OS over standard (cis)platinum-based chemotherapy. The effect size, as well as the broader eligibility criteria for EV+P position this regimen as a compelling preferred candidate for the new standard of care in front-line mUC treatment.Copyright © 2024. Published by Elsevier B.V.